BRIEF—Gilead presents positive data for Biktarvy

Gilead has presented 48-week results from a Phase II/III study of Biktarvy (bictegravir) for certain adolescents and children with HIV.

Results presented at the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) show the therapy sustained high rates of virologic suppression with a low incidence of study drug-related adverse events and no treatment-emergent resistance.

Lead investigator Aditya Gaur described the absence of treatment-emergent resistance as “a significant consideration for children and adolescents who are facing the prospect of long-term treatment.”